Capillarisin blocks prostate‐specific antigen expression on activation of androgen receptor in prostate carcinoma cells

Tsui, Ke‐Hung; Chang, Ying-Ling; Feng, Tsui-Hsia; Hou, Chen-Pang; Lin, Yu‐Hsiang; Yang, Pei-Shan; Lee, Bing-Wei; Juang, Horng‐Heng

doi:10.1002/pros.23463

Cited by 11 publications

(16 citation statements)

References 32 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were consistent with other studies in human breast carcinoma cells, MCF7, osteosarcoma and B‐lymphoblast cells, although some of them showed cell apoptosis was induced with higher Cap concentrations . The EC50 between DU145 and LNCaP after Cap treatments for 48 and 72 hours has shown no significant differences; however, recent study revealed that Cap blocks androgen activation on AR‐mediated prostate specific antigen expression in LNCaP cells . Whether Cap has the same effect on prostate normal epithelial cells still needs further investigations.…”

Section: Discussionsupporting

confidence: 89%

“…Prostate cancer is one of the most frequently diagnosed malignancies and the leading cause of cancer‐related deaths in men worldwide . In this study, we demonstrated that Cap suppressed cell growth without inducing apoptosis in androgen‐independent DU145 cells since the Cap did not significantly induce poly (ADP‐ribose) polymerase (PARP) cleavage form, an apoptotic marker, which is similar to a previous study in androgen‐dependent LNCaP cells . Moreover, the Cap‐inhibited cell growth of prostate carcinoma cells was due to its induction of cell cycle arrest at the G0/G1 phase (Figures and ).…”

Section: Discussionsupporting

confidence: 86%

“…1,22 In this study, we demonstrated that Cap suppressed cell growth without inducing apoptosis in androgen-independent DU145 cells since the Cap did not significantly induce poly (ADPribose) polymerase (PARP) cleavage form, an apoptotic marker, which is similar to a previous study in androgen-dependent LNCaP cells. 19 Moreover, the Cap-inhibited cell growth of prostate carcinoma cells was due to its induction of cell cycle arrest at the G0/G1 phase (Figures 1 and 4). These results were consistent with other studies in human breast carcinoma cells, MCF7, osteosarcoma and B-lymphoblast cells, although some of them showed cell apoptosis was induced with higher Cap concentrations.…”

Section: Discussionmentioning

confidence: 97%

“…[14][15][16] The EC50 between DU145 and LNCaP after Cap treatments for 48 and 72 hours has shown no significant differences; however, recent study revealed that Cap blocks androgen activation on AR-mediated prostate specific antigen expression in LNCaP cells. 19 Whether Cap has the same effect on prostate normal epithelial cells still needs further investigations. Our report is the first study to discover the potential mechanisms of Cap on the anti-proliferative effects of both androgen-dependent and -independent prostate carcinoma cells.…”

Section: Discussionmentioning

confidence: 99%

“…The cell pellets were harvested after cells were treated with or without Cap for 48 hours. Apoptosis detection and quantification were performed after treatment with Annexin V‐FITC (BioVision Inc, Milpitas, CA, USA) and propidium iodide (PI) for 1 hour using the FACSCalibur E6147 Cytometer (BD Biosciences) as previously described …”

Section: Methodsmentioning

confidence: 99%

See 4 more Smart Citations

The inhibitory effects of capillarisin on cell proliferation and invasion of prostate carcinoma cells

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

The inhibitory effects of capillarisin on cell proliferation and invasion of prostate carcinoma cells

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Scoparone alleviates hepatic fibrosis by inhibiting the TLR‐4/NF‐κB pathway

Gao

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

The aim of this study was to investigate the role of scoparone (SCO) in hepatic fibrosis. For this, we conducted in vivo and in vitro experiments. In vivo rats that were divided into six groups, control, carbon tetrachloride, and colchicine, as well as SCO groups, SCO50, SCO100, and SCO200 treated with 50, 100, and 200 mg/kg SCO doses, respectively. Furthermore, SCO was shown to inhibit Toll‐like receptor‐4 (TLR‐4)/nuclear factor kappa‐B (NF‐κB; TLR‐4/NF‐κB) signals by inhibiting TLR‐4, which in turn downregulates the expression of MyD88, promotes NF‐κB inhibitor‐α, NF‐κB inhibitor‐β, and NF‐κB inhibitor‐ε activation, while inhibiting NF‐κB inhibitor‐ζ. Subsequently, the decrease of phosphorylation of nuclear factor‐κB levels leads to the downregulation of the downstream inflammatory factors' tumor necrosis factor‐alpha (TNF‐α), interleukin‐6 (IL‐6), and IL‐1 beta, thus weakening hepatic fibrosis. Notably, the SCO200 treated group presented the most significant improvement. Hence, we conclude that SCO alleviates hepatic fibrosis by inhibiting TLR‐4/NF‐κB signals.

show abstract

Can Prostate Cancer Patients be Prescribed Chinese Herbal Medicine? A Review of its Potential Modulatory Effects on the Androgen Receptor

Wu,

Xian,

Zhang

et al. 2024

Integr Med Nephrol Androl

View full text Add to dashboard Cite

Prostate cancer (PCa) is a common disease among men worldwide, and conventional treatments for PCa typically involve surgery, chemotherapy, and radiation therapy. However, Chinese medicine (CM) has gained increasing attention as a complementary therapy for PCa treatment in recent decades. Chinese herbal medicine (CHM), a form of CM, has been shown to have good potential in PCa treatment, particularly by targeting the androgen receptor (AR), which plays a critical role in the development and progression of PCa. CHM interventions have been shown to inhibit AR activity, thereby delaying the disease’s progression. Moreover, most PCa patients at a later stage usually develop castration-resistant disease and drug resistance, posing a daunting challenge to clinical treatment. CHM offers several advantages, including improvement of patients’ quality of life, amelioration of clinical symptoms, and prolongation of survival; therefore, it offers a new direction for PCa treatment. This review aims to examine the current literatures on CM interventions targeting AR in PCa treatment. The review provides valuable insights into the potential benefits of CM as a complementary therapy for PCa treatment.

show abstract

Capillarisin blocks prostate‐specific antigen expression on activation of androgen receptor in prostate carcinoma cells

Abstract: Our results indicated that Cap inhibited growth of LNCaP cells. Cap effectively suppressed androgen activation on AR-mediated transactivation, which is AR-dependent through AR degradation and dissociation of AR-Hsp90 in prostate carcinoma cells.

Cited by 11 publications

References 32 publications

The inhibitory effects of capillarisin on cell proliferation and invasion of prostate carcinoma cells

The inhibitory effects of capillarisin on cell proliferation and invasion of prostate carcinoma cells

Scoparone alleviates hepatic fibrosis by inhibiting the TLR‐4/NF‐κB pathway

Can Prostate Cancer Patients be Prescribed Chinese Herbal Medicine? A Review of its Potential Modulatory Effects on the Androgen Receptor

Contact Info

Product

Resources

About